s include among others those relating to technology andproduct development market acceptance government regulation andregulatory approval processes intellectual property rights and litigationdependence on collaborative relationships ability to obtain financingcompetitive products industry trends and other risks identified inAdvanced Life Sciences' filings with the Securities and Exch
Date:8/30/2007
s include, among others, those relating to technology and
product development, market acceptance, government regulation and
regulatory approval processes, intellectual property rights and litigation,
dependence on collaborative relationships, ability to obtain financing,
competitive products, industry trends and other risks identified in
Advanced Life Sciences' filings with the Securities and Exchange
Commission. Advanced Life Sciences undertakes no obligation to update or
alter these forward-looking statements as a result of new information,
future events or otherwise.
'/>"/>SOURCE Advanced Life Sciences Holdings, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
Achieving Reliable Protein Quantitation Results Using ICAT Reagents, MALDITOF Mass Spectrometry, and Advanced Data Interpretation Tool2.
Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option3.
384 Well Pipetting Precision and Accuracy Testing Using the Sciclone Advanced Liquid Handler4.
WARF expands license agreement with Advanced Cell Technology5.
Rockwells $1M gift to UWM will support advanced automation research6.
Advanced CIO: Technology execs must trumpet their success7.
FDA approves advanced digital mammography system8.
Tech Digest: Inacom; St. Michaels, St. Clares hospitals; Merge eMed; Advanced Data-Comm; Blue Cross and Blue Shield9.
Wisconsins insurance companies use advanced IT to speed relief10.
$60 Million Available in Advanced Tech Competition11.
Advanced Life Sciences to Hit the Road For $30 Million in Funding